Imbria Pharmaceuticals Secures $57.5M and Appoints New CEO

Deal News | Apr 10, 2025 | SV Health Investors, LLC

Imbria Pharmaceuticals has successfully raised $57.5 million in a Series B financing round. SV Health Investors, LLC, played a significant role in this investment. The capital raise coincides with the appointment of Alvin Shih, MD, as the new Chief Executive Officer. This funding aims to bolster Imbria’s capabilities in developing novel medications. Dr. Shih’s appointment as CEO highlights a strategic leadership decision expected to enhance the company's progress in its pharmaceutical advancements.

Sectors

  • Pharmaceuticals
  • Venture Capital & Private Equity

Geography

  • United States – Both Imbria Pharmaceuticals and SV Health Investors are based in the United States, indicating this is where the primary activity is occurring.

Industry

  • Pharmaceuticals – The article is primarily concerned with Imbria Pharmaceuticals, a company involved in the development and commercialization of drugs.
  • Venture Capital & Private Equity – SV Health Investors, LLC, a private equity firm, is highlighted for providing significant investment funds in Imbria Pharmaceuticals' latest Series B round.

Financials

  • $57.5M – This represents the total capital raised by Imbria Pharmaceuticals in their Series B financing round.

Participants

NameRoleTypeDescription
Imbria PharmaceuticalsTargetCompanyA pharmaceutical company focused on developing innovative treatments, which has recently raised Series B funding.
SV Health Investors, LLCInvestorCompanyA private equity firm that invests in innovative healthcare companies, which invested in Imbria Pharmaceuticals in the Series B financing round.
Alvin Shih, MDCEOPersonThe newly appointed Chief Executive Officer of Imbria Pharmaceuticals, tasked with leading the company in its next phase of growth.